Nektar Therapeutics
NASDAQ:NKTRBiotechnology
-$1.24 today
- Market cap
- $1.03B
- Beta
- 1.15
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$6.39
Volume 0.71M
Average 1.00M
NKTR EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Nektar TherapeuticsNASDAQ: NKTR
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA remains negative
Q2 FY2026 EBITDA was -$42.24M, compared with -$33.79M a year earlier. Trailing-twelve-month EBITDA was -$134.39M.
Context
- EBITDA amounted to 248.1% of revenue in FY2025, up 160.0 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 13 analysts of -$99.53M (+27.4%) for the fiscal year ending Dec 2026, a step up from the -58.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$42.24M-15.0% QoQ
- Last fiscal yearDec 2025
- -$137M-58.0% YoY
- LTMJun 2026
- -$134.39M-53.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -25.0% | -117.6% | -92.6 pp |
| 1 year | -58.0% | +27.4% | +85.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (137M) USD
- Year-over-year change
- -58.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (137M) | -58.0% |
| FY2024 | 2024-12-31 | (86.7M) | +64.3% |
| FY2023 | 2023-12-31 | (243.11M) | +24.9% |
| FY2022 | 2022-12-31 | (323.87M) | +29.9% |
| FY2021 | 2021-12-31 | (461.82M) | — |
EBITDA vs competitors
How NKTR compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -53.9% is the 8th highest of 10, against a peer median of -7.0%.
- EBITDA amounts to 246.2% of revenue for NKTR, versus a peer median of 341.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $34.88M USD | +463.6% | — | 48.0% | |
| LTM Mar 2026 | $6.24M USD | +2711.1% | — | 1.6% | |
| LTM Mar 2026 | -$42.27M USD | -2.3% | — | — | |
| FY2025 | -€43.65M EUR | +7.0% | — | 1566.1% | |
| LTM Mar 2026 | -$50.64M USD | -7.0% | — | 32.2% | |
| LTM Jun 2024 | -$63.57M USD | — | — | 979.5% | |
| LTM Jun 2026 | -$123.6M USD | -14.3% | — | 117.7% | |
| LTM Jun 2026 | -$134.39M USD | -53.9% | — | 246.2% | |
| LTM Mar 2026 | -$159.87M USD | -61.9% | — | 341.0% | |
| LTM Mar 2026 | -€202.4M EUR | -4407.9% | — | 542.7% | |
| LTM Jun 2026 | -$419M USD | -48.6% | — | 358.1% | |
| Peer median (excluding NKTR) | — | -7.0% | — | 341.0% | |
Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 101.91M | 92.06M | 90.12M | 98.43M | 55.23M |
| Cost of Revenue | 24.9M | 21.64M | 36.64M | 30.69M | 0 |
| Gross Profit | 77.01M | 70.42M | 53.48M | 67.74M | 55.23M |
| Gross Margin | 75.6% | 76.5% | 59.3% | 68.8% | 100.0% |
| Research & Development | 400.27M | 218.32M | 114.16M | 120.91M | 117.33M |
| Selling, General & Admin | 122.84M | 92.33M | 77.42M | 76.75M | 68.67M |
| Operating Expenses | 523.11M | 310.66M | 190.9M | 172.94M | 186M |
| Depreciation & Amortization | 14.15M | 12.2M | 7.82M | 4.39M | 1.03M |
| EBITDA | (461.82M) | (323.87M) | (243.11M) | (86.7M) | (137M) |
| EBITDA Margin | -453.2% | -351.8% | -269.8% | -88.1% | -248.1% |
| Operating Income | (446.1M) | (240.24M) | (137.43M) | (105.2M) | (130.77M) |
| Operating Margin | -437.8% | -261.0% | -152.5% | -106.9% | -236.8% |
| Interest Income | 2.73M | 6.78M | 19.01M | 14.5M | 10.44M |
| Interest Expense | 47.31M | 28.91M | 25.33M | 28.11M | 26.18M |
| Other Income / Expenses | (77.18M) | (124.75M) | (138.83M) | (14M) | (33.44M) |
| Income Before Tax | (523.28M) | (364.98M) | (276.26M) | (119.2M) | (164.21M) |
| Pre-Tax Margin | -513.5% | -396.5% | -306.5% | -121.1% | -297.3% |
| Income Tax Expense | 557K | 3.22M | (200K) | (239K) | (138K) |
| Net Income | (523.84M) | (368.2M) | (276.06M) | (118.96M) | (164.08M) |
| Net Margin | -514.0% | -400.0% | -306.3% | -120.9% | -297.1% |
| EPS (Basic) | (42.90) | (29.51) | (21.79) | (8.68) | (9.73) |
| EPS (Diluted) | (42.90) | (29.51) | (21.79) | (8.68) | (9.73) |
| Weighted Avg Shares | 12.22M | 12.48M | 12.67M | 13.71M | 16.87M |
| Weighted Avg Shares (Diluted) | 12.22M | 12.48M | 12.67M | 13.71M | 16.87M |
Nektar Therapeutics
NASDAQ:NKTR
Intrinsic Alpha fair value
Locked
Current Price
$35.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.